Mesenchymal Stromal Cells: A Promising Cell Source for the Treatment of Inflammatory Cardiomyopathy

Author(s): C. Tschope, K. Miteva, H.-P. Schultheiss, S. Van Linthout

Journal Name: Current Pharmaceutical Design

Volume 17 , Issue 30 , 2011

Become EABM
Become Reviewer


Inflammatory cardiomyopathy is associated with a diffuse inflammation in the heart accompanied with cardiac fibrosis, cardiomyocyte apoptosis, and reduced capillary density. On the other hand, mesenchymal stromal cells (MSCs) have immunomodulatory, anti-fibrotic, anti-apoptotic, and pro-angiogenic features, making them attractive candidates for the treatment of inflammatory cardiomyopathy. The potential of MSC application for the treatment of myocarditis is supported by their beneficial effects in experimental models of acute and chronic inflammatory cardiomopathy. This review summarizes the cardioprotective features of MSCs and describes how MSCs are primed by the inflammatory environment to exert their protective effects. In view of clinical translation, searching for the optimal source of MSC and delivery route, allowing efficient and non-invasive cell application, the differences between MSCs of distinct origin and between diverse routes of application are outlined.

Keywords: Inflammatory cardiomyopathy, mesenchymal stromal cells, cell origin, cytokines, homing, administration route, myocarditis, monocytes, splenectomy, apoptosis

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2011
Page: [3295 - 3307]
Pages: 13
DOI: 10.2174/138161211797904136
Price: $65

Article Metrics

PDF: 15